Claims for Patent: 8,217,035

Summary for Patent: 8,217,035

Title:	Pyrimidine derivatives used as PI-3-kinase inhibitors
Abstract:	Phosphatidylinositol (PI) 3-kinase inhibitor compounds (I), their pharmaceutically acceptable salts, and prodrugs thereof; compositions of the new compounds, either alone or in combination with at least one additional therapeutic agent, with a pharmaceutically acceptable carrier; and uses of the new compounds, either alone or in combination with at least one additional therapeutic agent, in the prophylaxis or treatment of proliferative diseases characterized by the abnormal activity of growth factors, protein serine/threonine kinases, and phospholipid kinases. ##STR00001##
Inventor(s):	Burger; Matthew (Emeryville, CA), Ni; Zhi-Jie (Emeryville, CA), Pecchi; Sabina (Emeryville, CA), Atallah; Gordana (Emeryville, CA), Bartulis; Sarah (Emeryville, CA), Frazier; Kelly (Emeryville, CA), Smith; Aaron (Emeryville, CA), Verhagen; Joelle (Emeryville, CA), Zhang; Yanchen (Emeryville, CA), Wagman; Allan (Emeryville, CA), Ng; Simon (Emeryville, CA), Pfister; Keith (Emeryville, CA), Poon; Daniel (Emeryville, CA), Louie; Alicia (Emeryville, CA), Pick; Teresa (Emeryville, CA), Barsanti; Paul (Emeryville, CA), Iwanowicz; Edwin (Emeryville, CA), Fantl; Wendy (Emeryville, CA), Hendrickson; Thomas (Emeryville, CA), Knapp; Mark (Emeryville, CA), Merritt; Hanne (Emeryville, CA), Voliva; Charles (Emeryville, CA), Wiesmann; Marion (Emeryville, CA), Xin; Xiaohua (Emeryville, CA)
Assignee:	Novartis AG (Basel, CH)
Application Number:	12/161,537
Patent Claims:	1. The compound 4-(trifluoromethyl)-5-(2,6-dimorpholinopyrimidin-4-yl)pyridin-2-amine, of structure: ##STR00685## or a pharmaceutically acceptable salt thereof. 2. A composition, comprising a pharmaceutically acceptable carrier and an amount of a compound of claim 1 effective to inhibit PI3-K activity in a human or animal subject when administered thereto. 3. The composition of claim 2 further comprising at least one agent for the treatment of cancer. 4. The composition of claim 3, wherein the at least one agent for the treatment of cancer is vatalanib, imatinib, erlotinib, lapatinib, pertuzumab, trastuzumab, capecitabine, gemcitabine, irinotecan, paclitaxel, cisplatin, carboplatin, fulvestrant, dexamethasone, bevacizumab, docetaxel or gefitinib. 5. A method for treating ovarian cancer in a human or animal subject having ovarian cancer, comprising administering to the human or animal subject a composition comprising an amount of a compound of claim 1 effective to inhibit PI3-K activity in the human or animal subject. 6. The method of claim 5 further comprising administering to the human or animal subject at least one agent for the treatment of cancer. 7. The method of claim 6, wherein the at least one agent for the treatment of cancer is vatalanib, imatinib, erlotinib, lapatinib, pertuzumab, trastuzumab, capecitabine, gemcitabine, irinotecan, paclitaxel, cisplatin, carboplatin, fulvestrant, dexamethasone, bevacizumab, docetaxel or gefitinib.

Details for Patent 8,217,035

Applicant	Tradename	Biologic Ingredient	Dosage Form	BLA	Approval Date	Patent No.	Expiredate
Genentech, Inc.	HERCEPTIN	trastuzumab	For Injection	103792	09/25/1998		2039-02-26
Genentech, Inc.	HERCEPTIN	trastuzumab	For Injection	103792	02/10/2017		2039-02-26
Genentech, Inc.	AVASTIN	bevacizumab	Injection	125085	02/26/2004		2039-02-26
Genentech, Inc.	PERJETA	pertuzumab	Injection	125409	06/08/2012		2039-02-26
Genentech, Inc.	HERCEPTIN HYLECTA	trastuzumab and hyaluronidase-oysk	Injection	761106	02/28/2019		2039-02-26